There has been much recent controversy over the benefit and risks of the treatment of primary hyperlipidaemia. I Although clear guidelines exist from the British Hyperlipidaemia Association (BHA) and European Atherosclerosis Society (EAS)2,3 there are differing opinions over the merits of screening for and treating hyperlipidaemia.
Secondary hyperlipidaemia is, however, a less contentious subject. If an underlying cause is identified, appropriate treatment may allow early intervention in the disease, avoid subsequent complications, restore normal lipoprotein patterns and may also obviate the need for lipid-lowering therapy. Series et al," have demonstrated that by using a total serum cholesterol cut-off of 8· 0 mrnollL an unequivocal increase in the frequency of undiagnosed hypothyroidism is observed in hyperlipidaemic patients. The most frequently encountered and previously unsuspected causes in the lipoprotein clinic at Glasgow Royal Infirmary are alcohol excess, hypothyroidism, chronic renal failure and diabetes mellitus, although rarer conditions including nephrosis have also been discovered.
Questionnaires were sent to 46 practices in Glasgow, where public and practitioner awareness of hyperlipidaemia is high through local screening schemes, to assess general practitioner (GP) policies towards the systematic biochemical exclusion of causes of secondary hyperlipidaemia. As a secondary objective, GPs policies towards the referral of patients with hyperlipidaemia were also examined.
METHODS
Eighty questionnaires were sent to 46 practices (approximately 30DJo) in Glasgow. Practices were chosen at random, the total number being selected to give results on a total of at least 50 questionnaires.
Questionnaires assessed the following areas:
Number of patients referred to a lipoprotein clinic in the last 4 months 2 Referral criteria (the wording was non-specific to avoid leading questions concerning specific risk factor assessment) 3 Initial investigations performed by GPs i urea and electrolytes ii liver function tests iii serum albumin iv thyroid function tests v fasting glucose vi urinalysis vii blood pressure (Positive control question) 4 Further investigations performed prior to treatment if a patient was not referred to a lipoprotein clinic.
RESULTS
Sixty-four replies were received (80DJo). Fourteen respondents (22DJo) had referred patients to a lipoprotein clinic within the previous 4 months. Sixty-one respondents (96DJo) answered positively to the question about measurement of blood pressure (positive control). Twenty-eight (45DJo) of respondents indicated specific serum total cholesterol referral action limits, which ranged from 6· 5-10 mrnollL (median and mode 7· 8 mmol/L). Twenty-five (90DJo) of quoted action limits were between 7· 5 and 8· 5 mmollL. Most GPs (70DJo of respondents) made reference to co-existent risk factors for heart disease as a referral criterion.
The percentage of referred patients who had had initial investigations performed by GPs are shown in Fig. 1 . 
CONCLUSIONS
The questionnaire was designed to assess specific biochemical investigations performed in newly presenting patients, and not overall policies for the management of hyperlipidaemia. Biochemical exclusion of an underlying medical cause for hyperlipidaemia was performed variably by responders. These results suggest that many patients are not investigated with respect to possible secondary medical causes by GPs although no conclusions may be drawn about the proportion of patients subsequently referred to a lipoprotein clinic. The referral criteria specified by the great majority of the 80070 who responded were consistent with BHA and EAS guidelines, indicating that these may have been adopted successfully in the Glasgow region. In addition, the great majority of GPs who responded noted pre-existent risk factors amongst their referral criteria. In a small minority of cases referral limits were quite different from EAS and BHA guidelines.
Regardless of the debate over the potential to prevent coronary heart disease by screening for and treating hyperlipidaemia, current practice has resulted in large numbers of patients being screened Ann Clin Biochem 1994: 31 by GPs, and subsequently treated. It has been demonstrated, at least for hypothyroidism, that a proportion of these patients are suffering from treatable underlying medical causes, and that screening for hyperlipidaemia can lead to early presentation of these disorders." Precise prevalence figures for other secondary medical causes at different presenting total cholesterol concentrations are not yet available and are likely to vary nationally. It is likely, however, that failure to exclude secondary medical causes in patients presenting with hyperlipidaemia may lead to missed diagnoses.
Policies towards the exclusion of secondary hyperlipidaemia appear to be extremely variable. Although previously undiagnosed secondary disorders represent only a small proportion of the hyperlipidaemic population, the benefits of appropriate treatment have in many cases been established and it would therefore appear difficult to justify failing to exclude these conditions. Such a policy. however, would have widespread implications on the costs of investigating hyperlipidaemia, although these may be partly mitigated by savings in avoidable treatment. A detailed epidemiological and cost assessment of the implications of screening for secondary medical disease once hyperlipidaemia has been identified is needed.
